Icure Pharmaceutical Incorporation - Asset Resilience Ratio
Icure Pharmaceutical Incorporation (175250) has an Asset Resilience Ratio of 5.45% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Icure Pharmaceutical Incorporation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Icure Pharmaceutical Incorporation's Asset Resilience Ratio has changed over time. See 175250 equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Icure Pharmaceutical Incorporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 175250 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩4.49 Billion | 3.63% |
| Short-term Investments | ₩2.25 Billion | 1.82% |
| Total Liquid Assets | ₩6.75 Billion | 5.45% |
Asset Resilience Insights
- Limited Liquidity: Icure Pharmaceutical Incorporation maintains only 5.45% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Icure Pharmaceutical Incorporation Industry Peers by Asset Resilience Ratio
Compare Icure Pharmaceutical Incorporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Icure Pharmaceutical Incorporation (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Icure Pharmaceutical Incorporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 16.88% | ₩22.44 Billion ≈ $15.20 Million |
₩132.88 Billion ≈ $90.05 Million |
+11.73pp |
| 2023-12-31 | 5.15% | ₩8.56 Billion ≈ $5.80 Million |
₩166.14 Billion ≈ $112.59 Million |
-18.85pp |
| 2022-12-31 | 24.00% | ₩53.79 Billion ≈ $36.45 Million |
₩224.12 Billion ≈ $151.88 Million |
+12.67pp |
| 2021-12-31 | 11.33% | ₩24.42 Billion ≈ $16.55 Million |
₩215.45 Billion ≈ $146.01 Million |
+4.30pp |
| 2020-12-31 | 7.03% | ₩13.72 Billion ≈ $9.30 Million |
₩195.15 Billion ≈ $132.25 Million |
-1.77pp |
| 2019-12-31 | 8.80% | ₩18.99 Billion ≈ $12.87 Million |
₩215.80 Billion ≈ $146.24 Million |
-19.97pp |
| 2018-12-31 | 28.77% | ₩34.81 Billion ≈ $23.59 Million |
₩121.00 Billion ≈ $82.00 Million |
+11.05pp |
| 2017-12-31 | 17.72% | ₩9.55 Billion ≈ $6.47 Million |
₩53.90 Billion ≈ $36.53 Million |
+14.35pp |
| 2016-12-31 | 3.37% | ₩1.06 Billion ≈ $720.17K |
₩31.53 Billion ≈ $21.36 Million |
-- |
About Icure Pharmaceutical Incorporation
Icure Pharmaceutical Incorporation, a biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products in South Korea. The company offers functional, nature-derived, derma, and customized cosmetics products. It also offers eye gel, hydro nude gel, lip gel mask, and functional patch products; and sheet, mud, foil, and melting masks. In addition, the company provides … Read more